Italy boost lifts European markets off lows
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Medifast launches Trilivy, replacing its Optavia brand
AstraZeneca (AZN) Reports T010 Phase III ETHOS Trial Met its Primary Endpoint in Chronic Obstructive Pulmonary Disease
August 28, 2019 7:01 AM EDTAstraZeneca (NYSE: AZN) today announced positive results from the Phase III ETHOS trial for triple-combination therapy PT010 in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
At the standard budesonide dose, PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6mcg) demonstrated a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies glycopyrronium/formoterol fumarate 14.4/9.6mcg and PT009 (budesonide/formoterol fumarate 320/9.6mcg).
At half of the budesonide dose, PT010 (budesonide/glycopyrronium/formoterol fumarate 160/14.4/9.6mcg) also demonstrated a statistically-significant reduction in the rate of moderate or severe exacerbations compared with... More
